Wabisabi - we haven't heard from you for a while!
Hmm haven't covered this one...RA is certainly an overlapping condition but I tend to focus more heavily on OA...Thanks for pointing it out, good Snoop work.
High level research depicts it's a large market for Enbrel...in the Billions, this makes the Amgen deal quite lucrative for them in longer term.
Typically when a company takes over another, the taking over company's shares fall and the acquired company's shares match (goes up to the acquiring amount), ie $38 all cash offer, up 78%.
Enbrel is classed as a TNF inhibitor biologic.
The one thing I look for is the safety of the drug...
"ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening ...". 1
The other thing I then look for is the effect on Liver, Kidneys, Speen. Seems like Enbrel is better in this regards compared to Humira4. (Humira is also a TNF inhibitor).
Safety comparison to iPPS...well it's another clue as to where our trajectory may go....
safety safety...it's all about safety after efficacy.
$1.9 Billion USD deal for them...think we will be north of this once 008 comes home.
My views here.
References
1) https://www.enbrel.com/support/side-effects-safety-information#:~:text=ENBREL%20can%20cause%20serious%20side,fatal)%3B%20new%20or%20worsening
2) https://www.mdedge.com/familymedicine/article/31415/rheumatology/liver-enzymes-elevated-two-ra-biologics?sso=true
3) https://www.healthline.com/health/rheumatoid-arthritis/enbrel-vs-humira#takeaway
4) https://cdn.mdedge.com/files/s3fs-public/issues/articles/70186_main_13.pdf
- Forums
- ASX - By Stock
- PAR - Deal me in
Wabisabi - we haven't heard from you for a while!Hmm haven't...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $87.44M |
Open | High | Low | Value | Volume |
25.0¢ | 25.5¢ | 25.0¢ | $13.08K | 51.83K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 133489 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 25012 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 133489 | 0.250 |
8 | 129685 | 0.245 |
9 | 131700 | 0.240 |
5 | 146753 | 0.235 |
6 | 148982 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 25012 | 2 |
0.265 | 49987 | 1 |
0.270 | 10000 | 1 |
0.275 | 6347 | 2 |
0.280 | 59607 | 2 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
PAR (ASX) Chart |